↑ 薬物リストへ　← 戻る

Dalfampridine    (DrugBank: Dalfampridine)

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
4原発性側索硬化症1
13多発性硬化症／視神経脊髄炎10

4. 原発性側索硬化症　［臨床試験数：6，薬物数：16（DrugBank：8），標的遺伝子数：19，標的パスウェイ数：32］
Searched query = "Primary lateral sclerosis", "PLS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 6 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02868567
(ClinicalTrials.gov)		March 201617/3/2016Use of Dalfampridine in Primary Lateral SclerosisA Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral SclerosisMotor Neuron Disease, UpperDrug: dalfampridineWeill Medical College of Cornell UniversityHospital for Special Surgery, New YorkRecruiting18 Years99 YearsAll35Phase 1United States

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
10 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2014-003498-41-AT
(EUCTR)		22/09/201506/08/2015Effects of dalfampridine on mobility in the context of daily lifeEffects of dalfampridine on mobility in the context of daily life - Fampridine Study in Activities of Daily Living Motor behaviour and cognition in multiple sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Fampyra
INN or Proposed INN: FAMPRIDINE		Medical University of ViennaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		Austria
2NCT02391961
(ClinicalTrials.gov)		April 1, 20153/3/2015Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple SclerosisStudy and Treatment of Visual Dysfunction and Motor Fatigue in Multiple SclerosisMultiple Sclerosis;Internuclear Ophthalmoplegia;FatigueDrug: Dalfampridine;Drug: PlaceboVA Office of Research and DevelopmentNULLCompleted18 Years65 YearsAll23Phase 2United States
3NCT02259361
(ClinicalTrials.gov)		November 20141/10/2014Efficacy of Dalfampridine on Upper Extremity Function in Patients With MSEfficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot StudyMultiple SclerosisDrug: Sustained-release oral dalfampridine;Drug: PlaceboSheba Medical CenterNULLNot yet recruiting18 Years70 YearsBoth30Phase 4Israel
4NCT02166346
(ClinicalTrials.gov)		February 201416/6/2014Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)Transverse Myelitis;Neuromyelitis Optica;Idiopathic Transverse Myelitis;Myelitis NOSDrug: Dalfampridine;Drug: PlaceboJohns Hopkins UniversityAcorda TherapeuticsCompleted18 Years70 YearsAll24Phase 2United States
5NCT01535664
(ClinicalTrials.gov)		January 20127/2/2012An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MSMultiple SclerosisOther: Withdrawal of dalfampridine-ER 10mgAcorda TherapeuticsPrometrika, LLC;BCS Consulting, Inc.Completed18 Years70 YearsAll20United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT02006160
(ClinicalTrials.gov)		December 20116/6/2012Effects of Dalfampridine on Cognition in Multiple SclerosisEffects of Dalfampridine on Cognition in Multiple SclerosisMultiple SclerosisDrug: dalfampridine;Drug: placeboState University of New York at BuffaloNULLCompleted18 Years60 YearsAll61Phase 2;Phase 3United States
7NCT01444300
(ClinicalTrials.gov)		September 201120/9/2011Dalfampridine for Imbalance in Multiple SclerosisDalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot StudyMultiple Sclerosis;FatigueDrug: Dalfampridine;Drug: PlaceboOregon Health and Science UniversityAcorda TherapeuticsCompleted20 Years59 YearsAll24Phase 2United States
8NCT01337986
(ClinicalTrials.gov)		May 201113/4/2011Ampyra for Optic Neuritis in Multiple SclerosisDalfampridine After Optic Neuritis to Improve Visual Function in Multiple SclerosisMultiple Sclerosis;Optic NeuritisDrug: Dalfampridine/Placebo;Drug: Placebo/DalfampridineWashington University School of MedicineAcorda TherapeuticsCompleted18 Years55 YearsAll53Phase 2;Phase 3United States
9NCT01328379
(ClinicalTrials.gov)		March 201129/3/2011Study of Fampridine-ER Tablets in Patients With Multiple SclerosisDouble-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple SclerosisMultiple SclerosisDrug: Dalfampridine-ER 5mg;Drug: Dalfampridine-ER 10mg;Other: PlaceboAcorda TherapeuticsNULLCompleted18 Years70 YearsAll430Phase 3United States
10NCT01356940
(ClinicalTrials.gov)		November 201018/5/2011A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple SclerosisA Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple SclerosisMultiple SclerosisDrug: dalfampridine ER;Drug: placeboBrown, Theodore R., M.D., MPHAcorda TherapeuticsCompleted18 Years75 YearsAll43Phase 4United States

先頭へ